This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Pomerantz LLP Sues Inovio...
Business class action lawsuit

Pomerantz LLP Sues Inovio Pharmaceuticals Over Misleading Statements

Analysis based on 51 articles · First reported Feb 03, 2026 · Last updated Feb 20, 2026

Sentiment
-20
Attention
2
Articles
51
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against Inovio Pharmaceuticals, coupled with the United States===Food and and Drug Administration's decision on its lead product candidate, has led to a significant negative impact on Inovio Pharmaceuticals' stock price. This event highlights the risks associated with biotechnology companies facing regulatory hurdles and legal challenges, potentially affecting investor confidence in similar firms.

Biotechnology Legal Services
Event Summary

Pomerantz LLP has filed a class action lawsuit against Inovio Pharmaceuticals, Inc. and certain officers, alleging violations of federal securities laws. The lawsuit, filed in the United States===United States District Court for the Eastern District of Pennsylvania, claims that Inovio Pharmaceuticals made materially false and misleading statements regarding its CELLECTRA device manufacturing and the prospects of its INO-3107 Biologics License Application (BLA) for recurrent respiratory papillomatosis. Specifically, Inovio Pharmaceuticals allegedly overstated its ability to submit the BLA by mid-2024 and its eligibility for United States===Food and and Drug Administration accelerated approval or priority review. The truth began to emerge in August 2024 with a delay in BLA submission due to a manufacturing issue, and further in December 2025 when the United States===Food and and Drug Administration accepted the BLA on a standard review timeline, indicating insufficient information for accelerated approval. These revelations led to significant drops in Inovio Pharmaceuticals' stock price.

Key Actions
95 Inovio Pharmaceuticals made materially false and misleading statements
90 Pomerantz LLP filed class action lawsuit Inovio Pharmaceuticals
85 United States===Food and and Drug Administration accepted INO-3107 BLA on standard review timeline Inovio Pharmaceuticals
80 Inovio Pharmaceuticals issued press release announcing FDA acceptance of BLA on standard review
80 United States===Food and Drug Administration accepted INO-3107 BLA on standard rather than accelerated review Inovio Pharmaceuticals
70 Inovio Pharmaceuticals issued press release reporting financial results and business highlights
Entities Involved
stock
Inovio Pharmaceuticals
Inovio Pharmaceuticals is facing a class action lawsuit due to alleged materially false and misleading statements regarding its business, operations, and prospects, particularly concerning the INO-3107 BLA and CELLECTRA device. The lawsuit and the underlying issues have led to significant stock price declines and negative market sentiment.
Importance 100 Sentiment -80
priv
Pomerantz LLP
Pomerantz LLP has filed a class action lawsuit against Inovio Pharmaceuticals, Inc. and its officers, seeking damages for alleged violations of federal securities laws. This action positions Pomerantz LLP as a key player in representing investors affected by the alleged misconduct.
Importance 70 Sentiment 20
govactor
United States===Food and and Drug Administration
The United States===Food and and Drug Administration's decisions regarding the INO-3107 BLA, specifically the acceptance on a standard rather than accelerated review timeline, revealed that Inovio Pharmaceuticals had insufficient information to justify eligibility for accelerated approval. This regulatory decision significantly impacted Inovio Pharmaceuticals' stock price and commercial prospects.
Importance 60 Sentiment 0
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration's decisions regarding the INO-3107 BLA, specifically the acceptance on a standard rather than accelerated review timeline, directly impacted Inovio Pharmaceuticals, Inc.'s stock price and led to the allegations of misleading statements.
Importance 60 Sentiment 0
govactor
United States===United States District Court for the Eastern District of Pennsylvania
The United States===United States District Court for the Eastern District of Pennsylvania is the venue where the class action lawsuit against Inovio Pharmaceuticals has been filed. This court will oversee the legal proceedings and ultimately rule on the case.
Importance 50 Sentiment 0
exch
Nasdaq
Inovio Pharmaceuticals' securities are traded on Nasdaq, and the company's stock price experienced significant declines following the negative news related to the class action lawsuit and FDA decisions.
Importance 10 Sentiment 0
Relationships
Pomerantz LLP related ↔ Inovio Pharmaceuticals
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.